The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL) Meeting Abstract


Authors: Hamlin, P. A.; Cheson, B. D.; Farber, C. M.; Feldman, T.; Fenske, T. S.; Hess, B. T.; Khatcheressian, J. L.; Miller, C. B.; Munoz, J.; Patel, M. R.; Smith, S. M.; Smith, S. D.; Stevens, D. A.; Ye, J. C.; Steele, A.; Pandey, A.; Birrell, M.; Leeds, J.; Coffey, G.; Curnutte, J. T.
Abstract Title: The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL)
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 402s
Language: English
ACCESSION: WOS:000442916002581
DOI: 10.1200/JCO.2018.36.15_suppl.7511
PROVIDER: wos
Notes: Meeting Abstract: 7511 -- Source: Wos
Altmetric Score
MSK Authors
  1. Paul Hamlin
    168 Hamlin